CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

Sep 10, 2024 - 04:00

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

Read the original article

Tags:

Previous Article

CMN-005 by CoImmune for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of App...

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Rusan Pharma’s API Plant in Ankleshwar Receives USFDA GMP Approval

Rusan Pharma’s API Plant in Ankleshwar Receives USFDA G...

Jul 22, 2024

AusperBio AHB-137 gains breakthrough status in China for CHB

AusperBio AHB-137 gains breakthrough status in China fo...

Jul 12, 2024

STAT+: Narcan manufacturer aims to price over-the-counter kit under $50

STAT+: Narcan manufacturer aims to price over-the-count...

Apr 21, 2023